GlassScriptPhysician profile
Parag J Shah
NPI 1154316503
$3,110.32
in general payments reported to CMS, 2019-2025
30 companies · $905 in 2025
The $905 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $370 · 2021: $81.02 · 2022: $98.91 · 2023: $387 · 2024: $159 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $574.39 | 2019-2025 | Watchman Flx, General - Therapies |
| E.R. Squibb & Sons, L.L.C. | $277.86 | 2019-2023 | Eliquis |
| Novo Nordisk INC | $240.51 | 2019-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $210.17 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $180.98 | 2019-2020 | |
| Pfizer INC. | $160.18 | 2019-2022 | |
| Stryker Corporation | $136.53 | 2024 | Mako |
| Corcept Therapeutics | $125.00 | 2025 | Korlym |
| Allergan, INC. | $124.98 | 2020 | |
| Davol INC. | $119.86 | 2025 | Phasix Mesh |
| Abiomed | $113.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $98.72 | 2019 | |
| Edwards Lifesciences Corporation | $85.27 | 2022 | |
| Electromed, INC. | $71.63 | 2019-2025 | Smartvest |
| Amgen INC. | $70.56 | 2025 | Tezspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $67.09 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.82 | 2019-2020 | |
| Mylan Specialty L.P. | $63.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $57.52 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $47.23 | 2023 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $42.70 | 2019-2025 | Opsumit |
| Insmed, INC. | $28.72 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $28.09 | 2023 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $25.49 | 2019-2020 | |
| Philips North America LLC | $19.18 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.87 | 2025 | |
| Merck Sharp & Dohme LLC | $14.39 | 2019 | |
| Lilly USA, LLC | $13.27 | 2019 | |
| Circassia INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.